Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease
Status:
Completed
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, parallel-group study to evaluate rotigotine pharmacokinetics,
safety and tolerability following a single intramuscular dose of one of two different
formulations of LY03003 in patients with Parkinson's disease.